GENERAL COMMENTS
This is a revised manuscript of the study by John-Michael Gamble and colleagues that examine the risk of depression and self-harm associated with incretin-based therapies (DPP4-inhibitors or GLP-1 receptor agonists) in a large cohort of type 2 diabetes patients.
The authors have addressed the questions raised in my previous review. I still think this is an interesting study with some sophisticated statistical methods. The exclusion of patients with known psychiatric illness and patients using psychiatric drugs is an important change to the manuscript. I have no further comments.
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GENERAL COMMENTS
Thank you to the authors for their response to my comments. I am satisfied with their response and the relevant changes made, which I believe have significantly improved the quality of the manuscript. The inclusion of BMI data (Tables, 1, 2 and Appendix J) is reassuring in that people in higher BMI categories (on their own and in the hdps models) do not seem to be at risk of depression / selfharm with the new treatments.
One minor comment:-1.Abstract (Results): The unadjusted and adjusted HR's should be presented together for easier reading and to maintain consistency with the main body of the paper.
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